Ninety ALLEVIATE patients ( 43 % BILAG A , mean BILAG score 13.2 ) were randomized to receive 360 mg/m ( 2 ) ( n = 42 ) or 720 mg/m ( 2 ) ( n = 11 ) epratuzumab or placebo ( n = 37 ) , plus standard of care , in 12-week cycles .